Association between acetylcholinesterase and β-amyloid peptide in Alzheimer's cerebrospinal fluid

Chemico-Biological Interactions

Volumn 175, Issue 1-3, 2008, Pages 209-215

  García Ayllón, María Salud ^a   Silveyra, María Ximena ^a   Sáez Valero, Javier ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Alzheimer disease; Cerebrospinal fluid; Cholinesterase inhibitor

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; TACRINE;

ALZHEIMER DISEASE; ARTICLE; BRAIN; CEREBROSPINAL FLUID; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVITY; GLYCOSYLATION; HUMAN; LONG TERM CARE; NEUROLOGIC DISEASE; PATHOGENESIS; PATIENT MONITORING; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; GLYCOSYLATION; HUMANS;

EID: 50649125445     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.04.047     Document Type: Article

References (70)

1. Probst A., Langui D., and Ulrich J. Alzheimer's disease: a description of the structural lesions. Brain Pathol. 1 (1991) 229-239
2. Masters C.L., Multhaup G., Simms G., Pottgiesser J., Martins R.N., and Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4 (1985) 2757-2763
3. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., and Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 13 (1994) 45-53
4. Jarrett J.T., Berger E.P., and Lansbury P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
5. Andreasen N., and Blennow K. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides 23 (2002) 1205-1214
6. Davies P., and Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 (1976) 1403
7. Perry E.K., Perry R.H., Blessed G., and Tomlinson B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1 (1977) 189
8. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J. Neural. Transm. Suppl. 62 (2002) 181-187
9. Small D.H. Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?. Expert Opin. Emerg. Drugs 10 (2005) 817-825
10. Mesulam M.M., and Morán M.A. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann. Neurol. 22 (1987) 223-228
11. Ulrich J., Meier-Ruge W., Probst A., Meier E., and Ipsen S. Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol. 80 (1990) 624-628
12. Morán M.A., Mufson E.J., and Gómez-Ramos P. Cholinesterases colocalize with sites of neurofibrillary degeneration in aged and Alzheimer's brains. Acta Neuropathol. 87 (1994) 284-292
13. Geula C., and Mesulam M.M. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res. 498 (1989) 185-189
14. Wright C.I., Guela C., and Mesulam M.M. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 683-686
15. Inestrosa N.C., Alvarez A., Pérez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., and Garrido J. Acetylcholinestearse accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16 (1996) 881-891
16. Rees T., Hammond P.I., Soreq H., Younkin S., and Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol. Aging 24 (2003) 777-787
17. Lahiri D.K., Lewis S., and Farlow M.R. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J. Neurosci. Res. 37 (1994) 777-787
18. Mori F., Lai C.C., Fusi F., and Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 6 (1995) 633-636
19. Zimmermann M., Gardoni F., Marcello E., Colciaghi F., Borroni B., Padovani A., Cattabeni F., and Di Luca M. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J. Neurochem. 90 (2004) 1489-1499
20. Nitsch R.M., Slack B.E., Wurtman R.J., and Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258 (1992) 304-307
21. Rossner S., Ueberham U., Schliebs R., Pérez-Polo J.R., and Bigl V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol. 56 (1998) 541-569
22. Efthimiopoulos S., Vassilacopoulou D., Ripellino J.A., Tezapsidis N., and Robakis N.K. Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8046-8050
23. Muller F., Dumez Y., and Massoulié J. Molecular forms and solubility of acetylcholinesterase during the embryonic development of rat and human brain. Brain Res. 331 (1985) 295-302
24. Fishman E.B., Siek G.C., MacCallum R.D., Bird E.D., Volicer L., and Marquis J.K. Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann. Neurol. 19 (1986) 246-252
25. Sáez-Valero J., Sberna G., McLean C.A., and Small D.H. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J. Neurochem. 2 (1999) 1600-1608
26. Arendt T., Brückner M.K., Lange M., and Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochem. Int. 21 (1992) 381-396
27. Sberna G., Sáez-Valero J., Beyreuther K., Masters C.L., and Small D.H. The amyloid β-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J. Neurochem. 69 (1997) 1177-1184
28. Hu W., Gray N.W., and Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J. Neurochem. 86 (2003) 470-478
29. Melo J.B., Agostinho P., and Oliveira C.R. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci. Res. 45 (2003) 117-127
30. Sáez-Valero J., Fodero L.R., White A.R., Barrow C.J., and Small D.H. Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with beta-amyloid peptides. Brain Res. 965 (2003) 283-286
31. Sberna G., Sáez-Valero J., Li Q.X., Czech C., Beyreuther K., Masters C.L., McLean C.A., and Small D.H. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease. J. Neurochem. 71 (1998) 723-731
32. Sáez-Valero J., de Ceballos M.L., Small D.H., and de Felipe C. Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid beta-peptide. Neurosci. Lett. 325 (2002) 199-202
33. Soreq H., Ben-Aziz R., Prody C.A., Seidman S., Gnatt A., Neville L., Lieman-Hurwitz J., Lev-Lehman E., Ginzberg D., Lapidot-Lifson Y., and Zacut H. Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G + C-rich attenuating structure. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 9688-9692
34. Rotundo R.L. Asymmetric acetylcholinesterase is assembled in the Golgi apparatus. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 479-483
35. Méflah K., Bernard S., and Massoulié J. Interactions with lectins indicate differences in the carbohydrate composition of the membrane-bound enzymes acetylcholinesterase and 5'-nucleotidase in different cell types. Biochimie. 66 (1984) 59-69
36. Campoy F.J., Cabezas-Herrera J., and Vidal C.J. Interaction of AChE with Lens culinaris agglutinin reveals differences in glycosylation of molecular forms in sarcoplasmic reticulum membrane subfractions. J. Neurosci. Res. 33 (1992) 568-578
37. Sáez-Valero J., Sberna G., McLean C.A., Masters C.L., and Small D.H. Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease. Lancet 350 (1997) 929
38. Sáez-Valero J., Barquero M.S., Marcos A., McLean C.A., and Small D.H. Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 69 (2000) 664-667
39. Sáez-Valero J., Fodero L.R., Sjögren M., Andreasen N., Amici S., Gallai V., Vanderstichele H., Vanmechelen E., Parnetti L., Blennow K., and Small D.H. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. J. Neurosci. Res. 72 (2003) 520-526
40. Silveyra M.X., Cuadrado-Corrales N., Marcos A., Barquero M.S., Rábano A., Calero M., and Sáez-Valero J. Altered glycosylation of acetylcholinesterase in Creutzfeldt-Jakob disease. J. Neurochem. 96 (2006) 97-104
41. Sáez-Valero J., Mok S.S., and Small D.H. An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease. Acta Neurol. Scand. Suppl. 176 (2000) 49-52
42. García-Ayllón M.S., Silveyra M.X., Andreasen N., Brimijoin S., Blennow K., and Sáez-Valero J. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. J. Neurochem. 101 (2007) 1701-1711
43. Rudd P.M., Endo T., Colominas C., Groth D., Wheeler S.F., Harvey D.J., Wormald M.R., Serban H., Prusiner S.B., Kobata A., and Dwek R.A. Glycosylation differences between the normal and pathogenic prion protein isoforms. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13044-13049
44. Rudd P.M., Merry A.H., Wormald M.R., and Dwek R.A. Glycosylation and prion protein. Curr. Opin. Struct. Biol. 12 (2002) 578-586
45. Ermonval M., Mouillet-Richard S., Codogno P., Kellermann O., and Botti J. Evolving views in prion glycosylation: functional and pathological implications. Biochimie. 85 (2003) 33-45
46. Nielsen D., Gyllberg H., Ostlund P., Bergman T., and Bedecs K. Increased levels of insulin and insulin-like growth factor-1 hybrid receptors and decreased glycosylation of the insulin receptor alpha- and beta-subunits in scrapie-infected neuroblastoma N2a cells. Biochem. J. 380 (2004) 571-579
47. Massoulié J., Pezzementi L., Bon S., Krejci E., and Vallette F.M. Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 41 (1993) 31-91
48. Small D.H., Michaelson S., and Sberna G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem. Int. 28 (1996) 453-483
49. Soreq H., and Seidman S. Acetylcholinesterase-new roles for an old actor. Nat. Rev. Neurosci. 2 (2001) 294-302
50. Layer P.G. Nonclassical roles of cholinesterases in the embryonic brain and possible links to Alzheimer disease. Alzheimer Dis. Assoc. Disord. 9 (1995) 29-36
51. Arendt T. Alzheimer's disease as a loss of differentiation control in a subset of neurons that retain immature features in the adult brain. Neurobiol. Aging 21 (2000) 783-796
52. Soininen H., Halonen T., and Riekkinen P.J. Acetylcholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Acta Neurol. Scand. 64 (1981) 217-224
53. Appleyard M.E., Smith A.D., Wilcock G.K., Esiri M.M., and Decreased. CSF acetylcholinesterase activity in Alzheimer's disease. Lancet 2 (1983) 452
54. Appleyard M.E., Smith A.D., Berman P., Wilcock G.K., Esiri M.M., Neary D., and Bowen D.M. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Brain 110 (1987) 1309-1322
55. Marquis J.K., Volicer L., Mark K.A., Direnfeld L.K., and Freedman M. Cholinesterase activity in plasma, erythrocytes, and cerebrospinal fluid of patients with dementia of the Alzheimer type. Biol. Psychiatry 20 (1985) 605-610
56. Atack J.R., May C., Kaye J.A., Kay A.D., and Rapoport S.I. Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type. Ann. Neurol. 23 (1988) 161-167
57. Davidsson P., Paulson L., Hesse C., Blennow K., and Nilsson C.L. Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. Proteomics 1 (2001) 444-452
58. Parnetti L., Amici S., Lanari A., Romani C., Antognelli C., Andreasen N., Minthon L., Davidsson P., Pottel H., Blennow K., and Gallai V. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol. Sci. 23 (2002) S95-S96
59. Darreh-Shori T., Hellström-Lindahl E., Flores-Flores C., Guan Z.Z., Soreq H., and Nordberg A. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J. Neurochem. 88 (2004) 1102-1113
60. Darreh-Shori T., Meurling L., Pettersson T., Hugosson K., Hellström-Lindahl E., Andreasen N., Minthon L., and Nordberg A. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J. Neural. Transm. 113 (2006) 1791-1801
61. Ogane N., Giacobini E., and Struble R. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. Brain Res. 589 (1992) 307-312
62. Zhao Q., and Tang X.C. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur. J. Pharmacol. 455 (2002) 101-107
63. Rakonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol. Hung. 54 (2003) 183-189
64. Amici S., Lanari A., Romani R., Antognelli C., Gallai V., and Parnetti L. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. Mech. Ageing Dev. 122 (2001) 2057-2062
65. Carroll R.T., Lust M.R., and Emmerling M.R. Beta-amyloid levels predict cholinesterase activity in human cerebrospinal fluid. Neuroreport 10 (1999) 127-130
66. Chiappa S., Padilla S., Koenigsberger C., Moser V., and Brimijoin S. Slow accumulation of acetylcholinesterase in rat brain during enzyme inhibition by repeated dosing with chlorpyrifos. Biochem. Pharmacol. 49 (1995) 955-963
67. Kaufer D., Friedman A., Seidman S., and Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 393 (1998) 373-377
68. Keller M., Robitzki A., and Layer P.G. Anticholinesterase treatment of chicken retinal cells increases acetylcholinesterase protein independently of protein kinase C. Neurosci. Lett. 309 (2001) 21-24
69. Koenigsberger C., Chiappa S., and Brimijoin S. Neurite differentiation is modulated in neuroblastoma cells engineered for altered acetylcholinesterase expression. J. Neurochem. 69 (1997) 1389-1397
70. Dori A., Cohen J., Silverman W.F., Pollack Y., and Soreq H. Functional manipulations of acetylcholinesterase splice variants highlight alternative splicing contributions to murine neocortical development. Cereb. Cortex 15 (2005) 419-430